GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Issuance of Debt

Larimar Therapeutics (STU:ZA71) Issuance of Debt : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Issuance of Debt?

Larimar Therapeutics's Issuance of Debt for the three months ended in Dec. 2024 was €0.00 Mil.

Larimar Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.


Larimar Therapeutics Issuance of Debt Historical Data

The historical data trend for Larimar Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Larimar Therapeutics Issuance of Debt Chart

Larimar Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Issuance of Debt
Get a 7-Day Free Trial - - - - -

Larimar Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Larimar Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Larimar Therapeutics Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Larimar Therapeutics's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Larimar Therapeutics Business Description

Traded in Other Exchanges
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics Headlines

No Headlines